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1124Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a complex genetic cardiovascular disorder with substantial variability in
phenotypic expression and natural progression. Recent research demonstrates the incremental utility of
cardiac magnetic resonance in the diagnosis, therapeutic planning, and prognostication of this disease.
The increasing incorporation of multimodality imaging of hypertrophic cardiomyopathy in clinical prac-
tice will continue to improve our understanding of the subtlemorphologic differences and their prognos-
tic implications. (J Am Coll Cardiol Img 2011;4:1123–37) © 2011 by the American College of Cardiology
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bypertrophic cardiomyopathy (HCM) is
the most common genetic cardiovascular
disorder, with an estimated prevalence of
1:500 in the general population (1,2). It
s typically inherited as a Mendelian autosomal
ominant trait, with over 600 mutations identi-
ed in sarcomeric genes (3,4). Recently, mutations
n genes encoding Z-disc proteins and proteins in-
olved in calcium regulation have also been implicated
5). This genetic diversity together with modifier
enes and environmental factors form the basis of its
henotypic heterogeneity.
Symptoms of HCM can develop from childhood
nd include exertional dyspnea, chest pain, pre-
yncope, and syncope, resulting from differing com-
inations of dynamic left ventricular outflow tract
LVOT) obstruction, left ventricular (LV) diastolic
nd systolic dysfunction, and supraventricular/
entricular arrhythmias. Although many patients
emain asymptomatic with a benign natural history,
udden cardiac death (SCD) might be the initial
anifestation in many otherwise asymptomatic or
ildly symptomatic young people (1,6). Current
isk prediction models include prior SCD, family
istory of SCD, unexplained syncope, spontaneous
ustained ventricular tachycardia, nonsustained ven-
ricular tachycardia on continuous electrocardiogra-
hy (ECG) monitoring, abnormal exercise blood
ressure, and LV thickness 30 mm (6). Such
rediction models are far from perfect for several
easons. Although a low risk of SCD has been
emonstrated in those without the aforementioned
isk markers (7), the negative predictive value is
ikely overestimated, because not all cases of SCD
re captured in retrospective studies. Conversely,
he positive predictive value of individual risk fac-
ors is low, with the exception of prior aborted SCD
nd spontaneous sustained ventricular tachycardia
8). The concern remains that, if implantable car-ioverter defibrillators (ICDs) were inserted in all
atients with any “high-risk” feature, the incidence
f device complications would surpass the potential
enefits.
Emergence of Cardiac Magnetic Resonance in HCM
Traditionally, the diagnosis of HCM relies upon
clinical assessment and transthoracic echocardi-
ography (TTE) to identify features such as left
ventricular hypertrophy (LVH), systolic anterior
motion of the mitral valve, and LVOT obstruc-
tion. In many clinical scenarios, technical limita-
tions of echocardiography and heterogeneous
phenotypic expression made such evaluation dif-
ficult, and cardiac magnetic resonance (CMR)
has emerged as a useful adjunctive imaging mo-
dality to complement routine TTE (9). CMR is
unique in its high spatial and temporal resolution
with excellent contrast between blood pool and
myocardium, without limitation of either imag-
ing window or imaging plane. Late gadolinium
enhancement (LGE) sequences enable the iden-
tification of myocardial fibrosis, which is associ-
ated with poor outcome (10 –14). In our center
and many others, CMR imaging is routinely
performed in all new patients with suspected or
known HCM as part of a comprehensive workup
that also includes TTE with provocative maneu-
vers, exercise stress echocardiography, and trans-
esophageal echocardiography (TEE) in select
cases. Indeed, comprehensive CMR in the diag-
nostic workup of HCM is considered an appro-
priate use of technology (15,16). Although defin-
itive cost-effectiveness data are unavailable, data
are likely to be available in specific clinical
scenarios where CMR aids in further refinement
of the current strategies of diagnosis, screening,
treatment, and prognosis. Table 1 summarizes
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1125the details and limitations of the typical CMR
study for HCM.
In this review article, we discuss the role of
CMR in the diagnosis, treatment, and prognosis
of HCM, with a focus on the complementary
value of CMR in relation to standard imaging
modalities, and we examine some of the emerging
roles of CMR.
CMR and Diagnosis
The phenotypic heterogeneity of HCM is well-
recognized. This is further complicated because not
all patients with LVH have HCM, whereas HCM-
like pathophysiology with dynamic LVOT obstruc-
tion can be observed without LVH, in a subgroup
of patients with mitral valve and/or papillary muscle
abnormalities. Figure 1 summarizes the diagnostic
challenges faced by clinicians in both established
and suspected HCM. Figure 2 highlights the areas
where CMR potentially has incremental utility.
Although a more comprehensive algorithm detail-
ing the step-by-step diagnostic approach in HCM
has been detailed elsewhere (17), a simplified ap-
proach to the differential diagnosis of HCM has
been outlined in Figure 3. CMR enables the precise
characterization of subtle disease phenotypic varia-
tions (Figs. 4, 5, 6, and 7, Online Videos 1, 2, and
3), especially important for characterizing LVOT,
papillary muscle, subvalvular anatomy, and diagnos-
ing of atypical HCM. High image quality and
tissue characterization accurately identify the vari-
ous conditions that mimic the morphological ap-
pearance of HCM (Figs. 8 and 9, Online Videos 4
and 5). Reproducible volume and mass quantification
might also identify at-risk individuals with a family
history of HCM and can be used to screen for
pre-clinical disease.
Disease characterization: LVOT, papillary muscle, and
subvalvular anatomy. Resting or provocable LVOT
bstruction is present in 70% of cases and is an
mportant manifestation of HCM (18). It relates to
he complex anatomical relationships between the
eptum, LVOT, mitral valve, and papillary muscles.
n the majority of HCM patients, septal hypertro-
hy leads directly to LVOT obstruction (Fig. 4,
nline Video 1). However, some present with hyper-
rophy without obstruction, whereas others pres-
nt with dynamic LVOT obstruction and mini-
al septal hypertrophy. The latter is likely due to
variety of papillary muscle and subvalvular
bnormalities (19) (Fig. 5, Online Video 2). Such
omplexity highlights the importance of accurate an- Utomical assessment. TTE and TEE are the current
tandards in assessing LVOT anatomy and flow
rofile. The main advantage of CMR is in iden-
ifying the anatomy of the septal-systolic anterior
otion contact and subvalvular apparatus. Iso-
ated or concomitant mid-ventricular obstruction
elated to mid-ventricular hypertrophy is also
asily demonstrated.
The CMR studies have illustrated the contribu-
ion of abnormal mitral subvalvular morphology in
VOT obstruction (20,21) (Fig. 6, Online Video
). Compared with control subjects, HCM patients
ave a higher incidence of papillary muscle anom-
lies such as bifid or multiple accessory papillary
uscles, as well as anteroapical papillary muscle
isplacement that encroaches into the
VOT during systole (19,22). Figure 7
chematically illustrates the common pap-
llary muscle anatomical variations that
ontribute to LVOT obstruction. During
MR acquisition, careful attention is paid
n the short-axis cine images, with addi-
ional long-axis cine images specifically
lanned to demonstrate subvalvular anat-
my. This is especially important in pa-
ients with dynamic LVOT obstruction
ithout classic asymmetric septal hyper-
rophy. A 3-dimensional dataset of the
V with high spatial resolution is ob-
ained with a respiratory navigator ECG-
ated whole-heart sequence that allows
ffline multiplanar reconstruction of pap-
llary and subvalvular anatomy.
Although CMR assessment of the
VOT is primarily anatomical, LVOT ac-
eleration and flow turbulence can be diag-
osed as systolic signal void in flow-sensitive
radient echo sequences, and LVOT gradi-
nt can be quantified with phase contrast
ow-sensitive sequences. However, this is often tech-
ically challenging in HCM for a variety of reasons.
roper alignment of the imaging plane to obtain the
ighest flow velocities can be time consuming and
rone to errors. Intravoxel dephasing and signal loss
ue to phase offset errors also make the accurate
uantification of turbulent flow difficult. Imaging with
rovocation and during exercise is also difficult with
MR. New CMR sequences under development
ight allow the routine 3-dimensional acquisition of
he flow pattern and velocities not limited by imaging
lanes (23), real-time velocity encoding (24), as well as
ccurate measurement of turbulent jet velocities (25).
A B B
A N D
CMR
reson
ECG
HCM
cardio
ICD
defibr
LGE
enhan
LV
LVH
hyper
LVOT
tract
RV
SCD
TEE
echoc
TTE
echocntil then, echocardiography remains the “goldR E V I A T I O N S
A C R O N YM S
cardiac magnetic
ance
electrocardiography
 hypertrophic
myopathy
implantable cardioverter
illator
late gadolinium
cement
left ventricle/ventricular
left ventricular
trophy
 left ventricular outflow
right ventricle/ventricular
sudden cardiac death
transesophageal
ardiography
transthoracicstan-
outﬂow tract; SCD  sudd y sta
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1126dard” for flow quantification of LVOT obstruction in
HCM.
CMR assesses mitral regurgitation with diverse
techniques. Gauging severity on the basis of
turbulence-related signal void in various cine
sequences is fraught with errors, because it is
highly dependent on pulse sequence parameters.
Most commonly, visualizing the regurgitant jet
on flow-sensitive gradient echo sequences is com-
cated CMR Study for HCM: Potential Advantages and Limitations
Technical Details Information Obtained
e Balanced SSFP Septal thickness Im
Optionally, 3D SSFP Relationship between the
septum, mitral valve, and
subvalvular apparatus in the
LVOT obstruction
N
Global and regional
ventricular function
Q
Ventricular mass C
Phase-sensitive
inversion recovery
gradient echo
sequence
Extent and location of
myocardial ﬁbrosis
T
Respiratory navigator
gated ECG gated 3D
SSFP sequences
Papillary muscle anatomy L
Coronary artery anatomy E
SPAMM sequence Regional wall deformation A
Velocity-encoded cine
sequences
Aortic ﬂow velocities,
proﬁle, and volume
Q
LVOT ﬂow velocities and proﬁle Q
Mitral regurgitant volumes and
fractions
t 90° saturation recovery
pre-pulse followed
by gradient echo
readout sequences
Myocardial perfusion In
 cardiac magnetic resonance; ECG  electrocardiography; HCM  hypertroph
en cardiac death; SPAMM  spatial modulation of magnetization; SSFP  steadplemented with quantification, by subtracting tforward aortic flow derived from the velocity-
encoded phase contrast sequence, from stroke
volume derived from LV volume measurements
(26,27). Although CMR also demonstrates mi-
tral leaflet abnormalities, echocardiography re-
mains the test of choice because of superior
temporal resolution and various Doppler tech-
niques for hemodynamic information.
Disease characterization: atypical forms of HCM. In
otential Advantages Over
Echocardiography
Limitations of CMR
Techniques
e quality superior to
hocardiography
Availability and portability of
echocardiography is unlikely
to be matched by CMR
itation of imaging window
d imaging plane
3D cine sequences are currently
limited by acquisition time,
inferior spatial and temporal
resolution
tiﬁcation of ventricular
lumes, function, and mass
th excellent reproducibility
Functional information on
dynamic LVOT obstruction
might not be easily obtained
ared with transesophageal
hocardiography, CMR is
ninvasive
e characterization for
ocardial ﬁbrosis is
ique to CMR
Limited role in patients with
chronic renal failure due to
concern over nephrogenic
systemic ﬁbrosis
Quantiﬁcation of myocardial
ﬁbrosis is time consuming
Detection of diffuse myocardial
ﬁbrosis remains challenging
Selection of wrong nulling time
on LGE might make
measurement of myocardial
ﬁbrosis inaccurate
ization of papillary muscle
mber, extent, proximal and
tal attachments
3D information with a high
spatial resolution is not easily
obtainable
sion of coronary anomalies as
ernative cause of cardiac
hythmia and SCD
rate characterization of regional
formation: strain and strain rate
Data analysis to obtain strain
and strain rate remains time
consuming
Limited clinical utility
tiﬁcation of ﬂow velocities
d volume
Accuracy of ﬂow measurements
in HCM has not been
validated
tiﬁcation of mitral regurgitation
ation on myocardial perfusion
easily obtained with CMR, at
time of contrast injection for
E assessment
Data analysis to quantify
myocardial perfusion remains
the realm of advanced
research laboratory
Clinical implications of
abnormal ﬁndings not
well-established
rdiomyopathy; LGE  late gadolinium enhancement; LVOT  left ventricular
te free precession.Table 1. Typical Dedi
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1127with asymmetric septal hypertrophy, and hence a
septal to posterior wall ratio 1.3 is diagnostic of
CM (28,29). Subsequent studies, including those
ith CMR, showed that atypical cases of HCM are
ore common than previously thought (30,31). These
ange from diffuse global hypertrophy on 1 end of the
Geno
Pheno
Genotypic
Heterogeneity
Phenotypic
Heterogeneity
Other conditions may
mimic the hypertrophic
cardiomyopathy
Atypical 
distribution
of hypertrophy
HYPERTROPHY
Non-obstructive
 hypertrophic
cardiomyopathy
Hype
Obst
 Cardio
Figure 1. Diagnostic Challenges Faced by Clinicians in Suspecte
This ﬁgure demonstrates the potential difﬁculties in diagnosis of hy
heterogeneity. Patients within the same family might have differen
left ventricular outﬂow tract (LVOT) obstruction to minimal hypertro
Potential Utility of C
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•Athlete’s heart
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Figure 2. Potential Role of CMR in Management of HCM
This ﬁgure explains the potential utility of cardiac magnetic reso
potential role in establishing the diagnosis, pre-procedural plann
as in Figure 1.pectrum to focal segmental hypertrophy on the other
nd. The focal hypertrophy variant sometimes in-
olves only 1 to 2 myocardial segments, often with a
oncontiguous pattern of hypertrophy where hyper-
rophied segments are separated by regions of normal
hickness (30). Normal LV mass does not exclude
Concurrent mitral
valve abnormalities
Concurrent papillary
muscle abnormalities
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Delayed disease expression in gene carriers,
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1128HCM in these patients. Such a focal noncontiguous
pattern of hypertrophy is not usually seen in secondary
forms of hypertrophy (e.g., hypertension). In 12% of
HCM patients, focal segmental LV hypertrophy is
limited to the anterolateral free wall, posterior septum,
or apex (30,32). These areas are technically challeng-
ing for TTE, due to imaging window limitation, and
in 1 study, the diagnosis of HCM was missed in 6%
of patients by echocardiography (32).
Apical HCM (Fig. 6, Online Video 3) with
predominantly LV apical hypertrophy is commonly
missed on TTE, because of limited acoustic windows
and foreshortening, and CMR has incremental utility
here (33). Similarly, apical aneurysm can be missed on
noncontrast TTE in 40% of cases and is best visual-
ized on CMR (34). Apical aneurysms present as
dyskinesis or akinesis with a thin rim of myocardium,
often with transmural scarring on LGE, and are
associated with adverse outcomes with an annual
event rate of 11%. In addition, recent reports found
that HCM patients often have significant right ven-
tricular (RV) involvement with increased RV wall
thickness and mass compared with control subjects
(35). Assessment of RV by CMR is superior to
echocardiography.
Differential diagnosis. Accurate diagnosis of HCM
s important, because of the significant lifestyle
Figure 3. Simpliﬁed Approach to the Differential Diagnosis of H
This ﬁgure is a simpliﬁed diagnostic approach in a patient with incr
cessful, multimodality imaging is necessary. Abbreviations as in Figltering and familial implications. iHYPERTENSIVEHEARTDISEASEANDAORTICSTENOSIS.
Hypertensive heart disease and aortic stenosis both
present with concentric rather than asymmetrical
LVH. HCM and hypertensive heart disease occa-
sionally might be difficult to differentiate, but in
general, LV wall thickness of hypertensive heart
disease is 15 to 16 mm. Specific studies compar-
ing hypertensive heart disease and HCM with
CMR are sparse, although with improved image
quality, CMR is more sensitive in detecting differ-
ences in segmental wall thickness. Interestingly,
although myocardial fibrosis on LGE has tradition-
ally been considered rare in hypertensive heart
disease and aortic stenosis, a recent study demon-
strated patchy LGE in more than 50% of hyper-
tensive heart disease and aortic stenosis patients
with significant LVH (36). Another report also
suggested a potential prognostic role for LGE in
aortic stenosis (37). As such, LGE itself might not
be specific for HCM, and its prognostic utility in
other disorders needs to be studied further. In
addition, in a small group of patients with concom-
itant valvular aortic stenosis and LVOT obstruction
from asymmetric septal hypertrophy, CMR can
identify the site of jet turbulence and distinguish the
relative contributions of the 2 disease processes.
ATHLETE’S HEART. Athlete’s heart is character-
d LV thickness. Please note that for such an approach to be suc-
1 and 2.CM
easezed by a mildly enlarged LV cavity, symmetric
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1129thickening of the LV wall—typically 15 mm—
nd normal diastolic function on Doppler echo-
ardiography. CMR complements TTE in this
ondition, because it accurately measures LV
olumes, mass, and function, with high reproduc-
bility (9,38). Researchers used wall thickness
ndexed to end-diastolic ventricular volume to
istinguish athlete’s heart from HCM (39). De-
pite this, such differentiation remains difficult,
nd some subjects might have to undergo a period
f deconditioning to document reverse remodel-
ng as a definitive proof of athlete’s heart (40).
NONCOMPACTION. Noncompaction is character-
ized by prominent LV trabeculations, and differenti-
ation of compacted and noncompacted layers is often
difficult in echocardiography, especially without con-
trast. CMR is ideal for delineating compacted and
noncompacted layers. An end-diastolic ratio between
noncompacted and compacted layers of more than
2.4:1.0 is a proposed imaging criterion for noncom-
paction. CMR also precisely delineates the character-
Figure 4. Patient With “Typical” HCM and LVOT Obstruction
(A) Patient with “typical” HCM with marked basal septal hypertroph
raphy after amyl nitrite. Patient with “garden-variety” hypertrophic
LVOT obstruction. Also note the myocardial ﬁbrosis. Late gadolinium
cardial ﬁbrosis (arrows). See Online Video 1. Abbreviations as in Figistic abrupt transition zone between affected andnonaffected segments as well as diagnoses the com-
monly associated LV thrombus.
INFILTRATIVE HEART DISEASES. Infiltrative heart
iseases mimic HCM with LVH and its functional
onsequences. CMR plays an important role in
xcluding these conditions.
Fabry’s disease. Fabry’s disease is an X-linked reces-
ive glycolipid storage disease with deficient alpha-
alactosidase activity. The resulting phenotype is of
oncentric hypertrophy, with LGE found in 50% of
atients, typically in the basal inferolateral segment in
mid-myocardial distribution (41) (Fig. 8, Online
ideo 4).
Hypereosinophilic syndrome. Hypereosinophilic syn-
drome presents with apical fibrosis and mural
thrombus, frequently leading to apical cavity oblit-
eration, and therefore can sometimes mimic apical
HCM on TTE (42). Areas of increased subendo-
cardial signal intensity are often observed.
Sarcoidosis. Sarcoidosis usually presents with a re-
strictive cardiomyopathy with generalized LV thick-
CMR and (B) LVOT obstruction (arrow) on Doppler echocardiog-
ructive cardiomyopathy with severe basal septal hypertrophy and
hancement in long-axis (C) and short-axis (D) views showed myo-
1 and 2.y on
obst
enening, but asymmetric basal septal involvement can
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1130mimic HCM (43). The LGE pattern is variable, most
commonly affecting the basal and lateral segments.
Amyloidosis. Amyloidosis presents with diffuse LV
wall thickening and diffuse LGE associated with a
characteristic shortening of myocardial nulling time
on inversion recovery sequences (44,45) (Fig. 9,
Online Video 5).
Screening. Despite advances in gene testing in HCM,
mutations are only identified in 60% of index HCM
cases (3,4). Phenotypic heterogeneity, incomplete
Figure 5. Patient With “Obstructive Cardiomyopathy” With Min
The main pathology is the abnormal hypermobile biﬁd papillary
the anterior mitral valve leaﬂet (arrow, C), seen on CMR (diastol
post exercise LVOT obstruction (D). See Online Videos 1 and
Figures 1 and 2.
Figure 6. Apical HCM
Apical HCM with marked mid and apical hypertrophy on cine CMR
hypertrophied apex on late gadolinium enhancement sequences (B). Sepenetrance, and delayed disease presentation some-
times until adulthood also make it challenging to
screen for suspected carriers and detect preclinical disease
in definite carriers. Current strategy involves a combina-
tion of clinical assessment, ECG, and TTE at 12- to
18-month intervals from age 12 to adulthood, although
negative clinical and imaging tests cannot fully exclude
the risks of future disease development (46).
Although a large prospective study of HCM
screening with CMR has not been performed, CMR
l LVH
scle (arrows, A and B) resulting in systolic anterior motion of
] and systole [B]) and echocardiography (C). This causes severe
LVH  left ventricular hypertrophy; other abbreviations as in
Patchy late gadolinium enhancement (arrow) is observed in theima
mu
e [A
2.(A).
e Online Videos 1 and 3. Abbreviations as in Figures 1 and 2.
1.
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1131might detect subtle abnormalities and/or serial
changes that are otherwise not observed on echocar-
diography, enabling the detection of pre-clinical dis-
ease. In small studies, CMR detected abnormal wall
thickening in approximately 20% of asymptomatic
gene carriers not appreciated by echocardiography.
Pre-hypertrophic crypts in the basal and mid infero-
septum have been suggested as a sign of a mutation
carrier (47,48). In a recent study, high levels of serum
C-terminal propeptide of type I procollagen were
found in subjects with HCM-mutations without
Figure 7. Schematic Diagram of the Common Variations in Pap
Schematic diagram of the common variations in papillary muscle a
during diastole, the right image represents systole. (A) Normal pap
ment of the papillary muscles; (D) hypertrophied papillary muscles
chordal attachment to the mid-portion of the mitral valve (MV); and
LA  left atrium; LV  left ventricle; other abbreviation as in Figure
Figure 8. Patient With Fabry’s Disease
Cine sequence in the 3-chamber view demonstrates the concentric
(arrow) late gadolinium enhancement (B). See Online Video 4.LVH, as compared with control subjects (49). Parallel
to the research in strain imaging by echocardiography to
detect subclinical contractile dysfunction in carriers
(50,51), CMR myocardial tagging techniques have also
been investigated; however, studies remain sparse (52).
CMR and Treatment Strategies
Symptomatic patients with obstructive HCM intrac-
table to medical therapy can either undergo surgical
myectomy or alcohol septal ablation. CMR is an
y Muscle Anatomy in HCM
my in HCM (arrows). The left image represents the myocardium
muscle orientation; (B) biﬁd papillary muscles; (C) apical displace-
mainly mid-cavity obstruction during systole; (E) abnormal
elongated anterior MV leaﬂet. See Online Video 2. Ao  aorta;
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1132important adjunct in the pre-procedural planning
for both procedures. We perform pre-operative
CMR and perioperative TEE to precisely measure
the degree and extent of the anteroseptal and
inferoseptal hypertrophy as well as the relationship
of the septum with the anterior mitral valve leaflet,
subvalvular apparatus, and papillary muscle mor-
phology. Accurate pre-operative anatomical assess-
ment of the subvalvular anatomy has led to the
increasing recognition that septal myectomy might
need to be combined with mitral valve and chordae
remodeling and/or papillary muscle reorientation to
optimally relieve LVOT obstruction (53,54).
CMR is extensively used to assess the effective-
ness of alcohol septal ablation (55,56). CMR after
surgical myectomy or alcohol septal ablation pro-
vides insights on the effect of the respective proce-
dures on the interventricular septum (55). Surgical
myectomy predictably leads to a discrete resected
area in the anteroseptum, whereas alcohol septal
ablation leads to a variable pattern of myocardial
scar, usually inferiorly in the basal septum with
extension to the RV side of the septum. The
improvement of LVOT obstruction is also more
variable after alcohol septal ablation.
CMR and Prognosis
LGE. There is a growing body of published re-
orts on the role of LGE on CMR in HCM risk
tratification, but a large prospective study on
ow the data should be interpreted to alter
Figure 9. Patient With Cardiac Amyloidosis
Cine sequence in the 4-chamber view demonstrates diffuse concen
images showed extensive amyloid inﬁltration (arrows) with general
reduced myocardial nulling time on inversion recovery sequences (anagement is still lacking. The histological aorrelate of LGE in HCM seems to be increased
yocardial collagen rather than myocardial dis-
rray, which is also observed on histological
pecimens. Increased myocardial collagen is pos-
ulated to reflect microvascular ischemia and
icroscopic replacement fibrosis due to small
ntramural coronary arteriole dysplasia (57,58).
he latter finding correlates with LGE in myec-
omy specimens from patients who underwent
urgery for LVOT obstruction (58). An alterna-
ive hypothesis for LGE in HCM suggested that
he causative sarcomeric gene mutations might
ead to a phenotypic expression of increased
yocardial connective tissue deposition (59).
The prevalence of LGE is variable in different
ohorts. In those with manifest HCM, it varies
etween 40% and 80% (10–14,60). The commonly
ound LGE pattern is patchy, multifoci mid-
yocardial fibrosis, especially in regions of hyper-
rophy (Figs. 4B, 4D, and 6B). Other observed
atterns include diffuse confluent transmural septal
brosis and patchy septal fibrosis at RV insertion
oints.
LGE correlates with LV wall thickening
10,61) and inversely correlates with LV ejection
raction (61– 63). It also correlates with other
nown clinical markers of SCD (64). The asso-
iation between LGE and the detection of ven-
ricular arrhythmia on Holter monitoring sug-
ests the potential pathophysiologic link between
CM, myocardial fibrosis, arrhythmia, and ulti-
ately SCD (10 –14,60). Recent longitudinal
tudies suggest a strong association between LGE
left ventricular hypertrophy (A). Late gadolinium enhancement
gadolinium uptake, resulting in high signal intensity and a
ee Online Video 5.tric
izednd SCD (Table 2) (12–14). LGE shows prom-
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1133ise, but there is insufficient evidence for inserting
an ICD on the basis of LGE alone. Further
studies should establish the role of LGE in
identifying high-risk patients from among those
who are currently classified as intermediate-risk
with clinical criteria and do not otherwise qualify
for ICD insertion.
Certain aspects of LGE in HCM prognostica-
tion are technically challenging and worthy of
mention. Error in the appropriate myocardial null-
ing time might over- or underestimate true fibrosis
burden. The use of phase sensitive inversion recov-
ery sequences has greatly improved this aspect (65).
Although LGE is assessed qualitatively in routine
clinical practice, LGE in relation to overall LV
myocardial volume can be quantified with auto-
mated software. Various methods exist and most
commonly calculate the total areas of signal inten-
sity above a certain number of SDs (n 2 to 6) over
that of the mean signal intensity of nulled myo-
cardium (61,66 – 68). These differences in meth-
odology translate into differences in the quanti-
fied area of LGE and potentially impact on the
ability to generalize individual research studies.
The current assessment of myocardial fibrosis
contrasts areas of LGE with areas of presumed
“normal” nulled myocardium. Histological stud-
ies, however, suggest a global increase in myocar-
dial fibrosis that current LGE imaging tech-
niques cannot detect. New techniques such as T1
mapping (69) and equilibrium contrast CMR
(70) might offer alternatives to quantify the
Table 2. Summary of the Recent Prognostic Studies on the Role
O’Hanlon
N (% women) 217
Follow-up, yrs 3
Clinical (%)
NYHA functional class III/IV 14
Wall thickness 30 mm 6
History of syncope 16
History of sustained VT/VF 3
CMR
Prevalence of LGE (%) 63
Quantiﬁcation of LGE FWH
Outcome
Primary endpoint: LGE vs. no LGE Primary combined endpo
Cardiovascular deaths (5.9
FWHM  full-width at half maximum; HR  hazard ratio; ICD  implantable ca
ventricular tachycardia; other abbreviations as in Table 1.overall extent of myocardial fibrosis.With respect to LGE and prognosis, the relative
importance of the severity, extent, and location of
LGE as well as whether there is a threshold effect
below which fibrosis does not impact on prognosis
is uncertain.
Septal thickness and LV mass. The current guidelines
include LV thickness 30 mm on TTE as an
important prognostic criterion (6). The improved
accuracy of CMR in measuring LV thickness will
likely refine this. In addition, CMR provides accu-
rate and reproducible information on overall LV
mass. Investigators have studied the relative prog-
nostic value of LV wall thickness and mass by
CMR. HCM patients typically have a “thickness-
mass” mismatch because of the differing extent of
hypertrophy in individual LV segments. It was
found that LV mass indexed to body surface area
above 2 SDs of a healthy control cohort is a
sensitive but not specific predictor of outcome,
whereas an LV wall thickness 30 mm is a more
specific but less sensitive predictor (71). Future
studies will clarify how best to use this information
in management.
NewDevelopments in CMR Imaging of HCM
Several new developments in CMR imaging of
HCM are worth discussing, but their clinical ap-
plications remain undecided.
There has been increasing awareness of the
importance of ventricular vascular interactions in
LGE in HCM
l. (13) Bruder et al. (14) Rub
243 (39)
3.0
8
4
6
6
61
2 SD Quali
25% vs. 7%); HR 3.37
s. 1.2%); HR 4.45
LGE is associated with all-cause
mortality (OR: 5.47) and
cardiac mortality (OR: 8.01)
SCD
dis
0.0
erter deﬁbrillator; NYHA  New York heart association; OR  odds ratio; VF  veof
et a inshtein et al. (12)
(29) 424 (41)
.1 3.6
53
7
16
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M tative manual tracing
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and appropriate ICD
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1134found to have a higher pulse wave velocity than
matched control subjects, indicating increased
aortic stiffness (72). This was independently as-
sociated with lower peak oxygen consumption on
cardiopulmonary exercise testing (73). Whole-
heart CMR sequences also provided insight that
HCM patients have a steep angle between the
aortic root and the LV long axis, compared with
control subjects. The acuteness of this LV-aortic
root angle correlates with age and the observed
LVOT gradient (74). These early findings high-
light the potential impact HCM has on the aortic
vasculature and the usefulness of CMR in inves-
tigating this relationship.
CMR perfusion studies in HCM investigated
the role of microvascular dysfunction in intramu-
ral coronary arteriole dysplasia and subsequently
myocardial fibrosis as well as in blunting myocar-
dial blood flow during vasodilator stress, which
has been observed in HCM, especially subendo-
cardially (75). Furthermore, CMR spectroscopy
with 31-phosphorus demonstrated an altered
myocardial energy metabolic profile in HCM that
correlated with the severity of LGE (76). With
CMR spectroscopy, perhexiline, a modulator of
substrate metabolism, was shown to ameliorate
cardiac energetic impairment, correct diastolic
dysfunction, and increase exercise capacity in
symptomatic HCM patients (77).
Myocardial tagging quantifies myocardial me-
chanics parameters such as strain, strain rate, and
torsion and has been studied in HCM. NotGK, et al. American College of Cardi- magnetic resonancemyocardial segments and is inversely related to
severity (52,78). These findings are analogous to
strain measured by speckle tracking on echocar-
diography, where impaired longitudinal strain
was shown to correlate with fibrosis severity (79).
Conclusions
HCM is a heterogeneous disease with complex mor-
phological expression that requires accurate disease
characterization for optimal therapeutic planning and
risk-stratification. CMR has emerged as a useful
adjunct for these purposes. With the increasing incor-
poration of multimodality imaging in the clinical
assessment of HCM, our understanding of the signif-
icance of subtle morphological differences will con-
tinue to grow, and further research will define new
prognostic markers and improve current treatment
strategies.
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